Exploring low‐dose glucagon for exercise‐induced hypoglycaemia in type 1 diabetes: A randomised controlled trial
Authors' conclusion
Low-dose native glucagon did not offer any advantages in preventing exercise-induced hypoglycaemia in individuals with T1D, regardless of glucagon dosing variations.
Study context
- Population
- Adults with T1D undergoing 60-min moderate-intensity cycle ergometry (≈50% HRmax) fasted, then 2 h rest; pump users reduced basal insulin by 50% during cyclingcrossover
- Participants
- 22 adults
- Comparison
- Single s.c. glucagon 150 μg vs split 75 μg ×2 vs placebo
- Primary endpoint
- Occurrence of exercise-induced hypoglycaemia
Methodological detailssingle-blinded, three-arm, crossover
- Single-blinded
- Three-arm
- Crossover
Primary result
As reported in the abstract
Hypoglycaemia events
G150
7
events
G75*2
5
events
Placebo (PBO)
6
events
P = 0.078
Further findings
Mean PG throughout the trial
Time with PG in target range (3.9-10.0 mmol/L)
Time above range
- Mean plasma glucose (PG) throughout the trial — Lower mean PG with PBO vs both glucagon arms
- p = 0.015
- Time with PG in target range (3.9-10.0 mmol/L) — Higher time in range with PBO vs both glucagon arms
- p = 0.005
- Time above range — Less time above range with PBO
- p = 0.007
Original publication
Exploring low‐dose glucagon for exercise‐induced hypoglycaemia in type 1 diabetes: A randomised controlled trial. Diabet Med. Published 23 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →